Download PDF
Arthritis und Rheuma 2010; 30(04): 211-218
DOI: 10.1055/s-0037-1618021
Vaskulitiden
Schattauer GmbH

Plasmaaustauschbehandlung bei systemischen Vaskulitiden

Plasma exchange in systemic vasculitides
M. Zänker
1   Evangelisch-Freikirchliches Krankenhaus und Herzzentrum Brandenburg in Bernau, Rheumazentrum Nord-Brandenburg, Abteilung für Innere Medizin (Gastroenterologie, Nephrologie, Rheumatologie)
› Author Affiliations
Further Information

Publication History

Publication Date:
26 December 2017 (online)

    Permissions and Reprints

Zusammenfassung

Der therapeutische Plasmaaustausch ist als extrakorporales Blutreinigungsverfahren zur Elimination höhermolekularer Plasmabestandteile geeignet. Hierzu zählen u. a. pathogene Antikörper, Immunkomplexe, Kryoglobuline oder Leichtketten. Zu den durch randomisiert-kontrollierte Studien bestätigten Behandlungsindikationen gehören auch systemische Vaskulitiden mit schwerer Nieren- und/oder Lungenbeteiligung. Metaanalysen bisheriger Studien bestätigen die eindeutige Wirksamkeit des Plasmaaustausches bzgl. der Sicherung einer dialyseunabhängigen Nierenfunktion. Für die wirksame Beseitigung von Autoantikörpern sind fünf bis sieben Behandlungen innerhalb von sieben bis zehn Tagen optimal. Um nach der Apherese eine Resynthese der pathogenen Antikörper zu verhindern, ist eine synchronisierte immunsuppressive Therapie erforderlich. Der Plasmaaustausch kann, je nach Krankheitsbild, Stadium und Gerinnungssituation, gegen verschiedene Substituate erfolgen. Behandlungen mit FFP (Fresh Frozen Plasma) sind deutlich häufiger mit Nebenwirkungen verbunden als der Austausch gegen Albuminlösungen.

Summary

Therapeutic plasma exchange is an extracorporeal blood purification technique appropriate for the removal of large molecular weight substances from the plasma. Such substances include pathogenic antibodies, immune complexes, cryoglobulins, myeloma light chains. Reflecting evidence from randomized controlled studies today the highest indication categories include systemic vasculitides with severe renal involvement and/or pulmonary hemorrhage. Metanalysis of previous studies confirm a clear benefit of plasma exchange to preserve dialysis independent renal function. For effective immunoglobulin elimination 5 to 7 plasma exchanges within 7 to 10 days are optimal. In order to avoid immunoglobulin resynthesis, additional simultaneous immunosuppressive therapy is required. Depending on indication, different replacement fluids, removal rates and frequencies are recommended. Adverse reactions are substantially more common with fresh frozen plasma (FFP) than with albumin replacement.

Schlüsselwörter

Apherese - Plasmaaustausch - Vaskulitis - Glomerulonephritis

Keywords

Apheresis - plasma exchange - vasculitis - glomerulonephritis
 

  • Literatur

  • 1 Apherese Standard der Deutschen Arbeitsgemeinschaft für Klinische Nephrologie e.V. Mitt Klin Nephrol 2002; XXXI: 103.
    Google Scholar
  • 2 Adams WS. A method of human plasmapheresis. Proc Soc Exp Biol Med 1952; 80: 377.
    CrossrefPubMedGoogle Scholar
  • 3 Cole E, Cattran D, Magil A, Greenwood C. et al. A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis. The Canadian Apheresis Study Group. Am J Kidney Dis 1992; 20 (03) 261-269.
    CrossrefPubMedGoogle Scholar
  • 4 Cornelissen JJ, Goltermann AFL, Kerckhaert JAM. Fixed IgM reduction in plasma exchange: A standardized method for calculating the volume to be removed per session. Plasma Ther Transfus Techno 1985; 5: 365.
    Google Scholar
  • 5 Dihazi H, Zaenker M, Blaschke S. Analysis of proteomic profiles during immunoadsorption in severe refractory rheumatoid arthritis. Z Rheumatol 2008; Suppl I: 50.
    Google Scholar
  • 6 Felson DT, LaValley MP, Baldassare AR. et al. The Prosorba column for treatment of refractory rheumatoid arthritis: a randomized, double-blind, sham-controlled trial. Arthritis Rheum 1999; 42 (10) 2153-2159.
    CrossrefPubMedGoogle Scholar
  • 7 Ferri C. Mixed cryoglobulinemia. Orphanet Journal of Rare 2008; 3: 25.
    Google Scholar
  • 8 Glockner WM, Sieberth HG, Wichmann HE. et al. Plasma exchange and immunosuppression in rapidly progressive glomerulonephritis: a controlled, multi-center study. Clin Nephrol 1988; 29 (01) 1-8.
    PubMedGoogle Scholar
  • 9 Hess DC, Sethi K, Awad E. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus and antiphospholipid antibodies: effective treatment with plasma exchange and immunosuppression. J Rheumatol 1992; 19 (09) 1474-1478.
    Google Scholar
  • 10 Jayne DR, Gaskin G, Rasmussen N. et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007; 18 (07) 2180-2188.
    CrossrefPubMedGoogle Scholar
  • 11 Kaplan AA. A simple and accurate method for prescribing plasma exchange. ASAIO Trans 1990; 36 (03) M597-599.
    Google Scholar
  • 12 Keller AJ, Urbaniak SJ. Intensive plasma exchange on the cell separator: effects on serum immunoglobulins and complement components. Br J Haematol 1978; 38 (04) 531-540.
    CrossrefPubMedGoogle Scholar
  • 13 Kolins J, Jones JM. Therapeutic Apheresis. Arlington: American Association of Blood Banks; 1983: 2.
    Google Scholar
  • 14 Madore F, Lazarus JM, Brady HR. Therapeutic plasma exchange in renal diseases. J Am Soc Nephrol 1996; 7 (03) 367-386.
    PubMedGoogle Scholar
  • 15 Mauri JM, Gonzales MT, Poveda R. Therapeutic plasma exchange in the treatment of rapidly progressive glomerulonephritis. lasma Ther Transfus Technol 1985; 6: 587.
    Google Scholar
  • 16 Mokrzycki MH, Kaplan AA. Therapeutic plasma exchange: complications and management. Am J Kidney Dis 1994; 23 (06) 817-827.
    CrossrefPubMedGoogle Scholar
  • 17 Mukhtyar C, Guillevin L, Cid MC. et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009; 68 (03) 310-317.
    CrossrefPubMedGoogle Scholar
  • 18 Pagnoux C, Korach JM, Guillevin L. Indications for plasma exchange in systemic lupus erythematosus in 2005. Lupus 2005; 14 (11) 871-877.
    CrossrefPubMedGoogle Scholar
  • 19 Pagnoux C. Plasma exchange for systemic lupus erythematosus. Transfus Apher Sci 2007; 36 (02) 187-193.
    CrossrefPubMedGoogle Scholar
  • 20 Pusey CD, Rees AJ, Evans DJ. et al. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int 1991; 40 (04) 757-763.
    CrossrefPubMedGoogle Scholar
  • 21 Rifle G, Dechelette E. Treatment of rapidly progressive glomerulonephritis by plasma exchange and methylprednisolone pulses. A prospective randomized trial of cyclophosphamide. Interim analysis. The French Cooperative Group. Prog Clin Biol Res 1990; 337: 263-267.
    PubMedGoogle Scholar
  • 22 Samadi-Ahadi N, Precht S, Zaenker M. Immunadsorption mit Tryptophan-Adsorber 350 bei Rheumatoider Arthritis. Z Rheumatol 2007; Suppl I: 83.
    PubMedGoogle Scholar
  • 23 Smith JW, Weinstein R. Therapeutic apheresis: a summary of current indication categories endorsed by the AABB and the American Society for Apheresis. Transfusion 2003; 43 (06) 820-822.
    CrossrefPubMedGoogle Scholar
  • 24 Stigelman Jr. WH, Henry DH, Talbert RL, Townsend RJ. Removal of prednisone and prednisolone by plasma exchange. Clin Pharm 1984; 3 (04) 402-407.
    Google Scholar
  • 25 Sutton DM, Nair RC, Rock G. Complications of plasma exchange. Transfusion 1989; 29 (02) 124-127.
    CrossrefPubMedGoogle Scholar
  • 26 Terman DS, Buffaloe G, Sullivan M. Extracoporeal immunoadsorption: Initial experience in human systemic lupus erythematosus. Lancet 1979; II: 824.
    PubMedGoogle Scholar
  • 27 Walters GD, Willis NS, Craig JC. Intervention for renal vasculitis in adults. A systematic review. BMC Nephrology 2010; 11: 12.
    CrossrefPubMedGoogle Scholar